亿帆医药：重酒石酸去甲肾上腺素注射用浓溶液（4mg/4mL）获新加坡注册批文

Group 1 - Company SciGen Pte. Ltd., a wholly-owned subsidiary of Yifan Pharmaceutical, has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing registration of its pharmaceutical product, Norepinephrine SciGen, a concentrated solution for injection [1] - The product is indicated for the management of severe acute hypotension in adults and was approved domestically in March 2023, with the registration application submitted to HSA in December 2023 [1] - The approval supports the company's strategy for "full-category, multi-region" international expansion, with domestic production lines receiving international certification [1] Group 2 - The approval is not expected to have a significant short-term impact on the company's operating performance, but successful commercialization in the future could yield positive effects [1] - The operational situation may be influenced by overseas policies and exchange rate fluctuations, indicating some uncertainty for investors [1]